AU2018351494C1 - Dantrolene prodrugs and methods of their use - Google Patents
Dantrolene prodrugs and methods of their useInfo
- Publication number
- AU2018351494C1 AU2018351494C1 AU2018351494A AU2018351494A AU2018351494C1 AU 2018351494 C1 AU2018351494 C1 AU 2018351494C1 AU 2018351494 A AU2018351494 A AU 2018351494A AU 2018351494 A AU2018351494 A AU 2018351494A AU 2018351494 C1 AU2018351494 C1 AU 2018351494C1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- dantrolene
- aspects
- 26alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023278113A AU2023278113B2 (en) | 2017-10-20 | 2023-12-08 | Dantrolene prodrugs and methods of their use |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US62/575,124 | 2017-10-20 | ||
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| US62/674,422 | 2018-05-21 | ||
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | DANTROLENE PRODRUGS AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023278113A Division AU2023278113B2 (en) | 2017-10-20 | 2023-12-08 | Dantrolene prodrugs and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2018351494A1 AU2018351494A1 (en) | 2020-04-30 |
| AU2018351494B2 AU2018351494B2 (en) | 2023-09-14 |
| AU2018351494C1 true AU2018351494C1 (en) | 2025-10-23 |
Family
ID=64277793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018351494A Active AU2018351494C1 (en) | 2017-10-20 | 2018-10-19 | Dantrolene prodrugs and methods of their use |
| AU2023278113A Active AU2023278113B2 (en) | 2017-10-20 | 2023-12-08 | Dantrolene prodrugs and methods of their use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023278113A Active AU2023278113B2 (en) | 2017-10-20 | 2023-12-08 | Dantrolene prodrugs and methods of their use |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11352347B2 (https=) |
| EP (2) | EP4574832A3 (https=) |
| JP (2) | JP7252963B2 (https=) |
| KR (1) | KR102652642B1 (https=) |
| CN (1) | CN111344286A (https=) |
| AU (2) | AU2018351494C1 (https=) |
| BR (1) | BR112020007858A2 (https=) |
| CA (1) | CA3079558A1 (https=) |
| CO (1) | CO2020006193A2 (https=) |
| ES (1) | ES3016835T3 (https=) |
| IL (1) | IL274045B2 (https=) |
| MA (1) | MA50403A (https=) |
| MX (2) | MX2020003400A (https=) |
| MY (1) | MY201417A (https=) |
| NZ (1) | NZ763377A (https=) |
| SG (1) | SG11202003452XA (https=) |
| UA (1) | UA127738C2 (https=) |
| WO (1) | WO2019079721A1 (https=) |
| ZA (1) | ZA202002779B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020007858A2 (pt) * | 2017-10-20 | 2020-10-27 | Eagle Research Labs Limited | composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto |
| SG11202104833YA (en) * | 2018-11-27 | 2021-06-29 | Eagle Res Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| IL296517A (en) * | 2020-04-10 | 2022-11-01 | Eagle Pharmaceuticals Inc | Methods of treating sars-cov-2 infections |
| US20230149364A1 (en) * | 2020-04-10 | 2023-05-18 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| WO2021207445A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
| WO2021207444A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating severe acute respiratory syndrome |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) * | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20080206332A1 (en) | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| EP2219605B1 (en) | 2007-10-09 | 2015-08-19 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| FR2944525B1 (fr) | 2009-04-17 | 2011-06-24 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| EP2765860B1 (en) | 2011-10-13 | 2016-08-17 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| CN105209030B (zh) | 2013-03-15 | 2018-06-12 | 罗莎琳德富兰克林医科大学 | 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物 |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| CA2946253C (en) | 2013-05-06 | 2022-08-09 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| EP2994132A4 (en) | 2013-05-08 | 2016-11-16 | Univ Howard | COMPOSITIONS AND METHOD FOR TREATING NEURONAL ISCHEMIC REPERFUSION DAMAGE |
| HUP1300720A2 (hu) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| JPWO2015182625A1 (ja) | 2014-05-26 | 2017-06-08 | 国立大学法人京都大学 | Ｒａｓ活性阻害薬及びその用途 |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| CN108366963A (zh) | 2015-10-20 | 2018-08-03 | B.布劳恩梅尔松根股份公司 | 包含丹曲林的水性组合物 |
| BR112020007858A2 (pt) * | 2017-10-20 | 2020-10-27 | Eagle Research Labs Limited | composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto |
| SE542780C2 (en) | 2018-09-15 | 2020-07-07 | Coloreel Group AB | A system and method for in-line treatment of thread |
-
2018
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/pt active Search and Examination
- 2018-10-19 MA MA050403A patent/MA50403A/fr unknown
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/ja active Active
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 EP EP25160825.3A patent/EP4574832A3/en active Pending
- 2018-10-19 ES ES18801102T patent/ES3016835T3/es active Active
- 2018-10-19 AU AU2018351494A patent/AU2018351494C1/en active Active
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/es unknown
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/ko active Active
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/zh active Pending
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en not_active Ceased
- 2018-10-19 NZ NZ763377A patent/NZ763377A/en unknown
- 2018-10-19 EP EP18801102.7A patent/EP3697779B1/en active Active
- 2018-10-19 MY MYPI2020001973A patent/MY201417A/en unknown
- 2018-10-19 UA UAA202002979A patent/UA127738C2/uk unknown
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/es unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/es unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US12269815B2/en active Active
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/ja active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113B2/en active Active
-
2024
- 2024-10-17 US US18/918,855 patent/US20250145593A1/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| BUNDGAARD, HANS; JOHANSEN, MARIANNE: "Pro-drugs as drug delivery systems. VIII. Bioreversible derivatization of hydantoins by N-hydroxymethylation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 5(1), 1980, pages 67 - 77 * |
| SNYDER H R ET AL: "1-[(5-arylfurfurylidene)amino]hydantoins. A new class of muscle relaxants", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 10, 1 September 1967 (1967-09-01), pages 807 - 809, DOI: 10.1021/JM00317A011 * |
| Varia, S.A. et al, 'Phenytoin Prodrugs III: Water-Soluble Prodrugs for Oral and/or Parenteral Use', Journal of pharmaceutical Sciences, 1984, 73(8), pp. 1068-1073 * |
| WESSELS F L ET AL: "Synthesis and skeletal muscle relaxant activity of 3-(aminoacyl)-1-[[[5-(substituted phenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinediones", J. PHARM. SCI. vol. 70, no. 9, 1981, pages 1088 - 1090 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018351494C1 (en) | Dantrolene prodrugs and methods of their use | |
| Sit et al. | Pharmacology, pharmacokinetics, and tissue disposition of zwitterionic hydroxyiminoacetamido alkylamines as reactivating antidotes for organophosphate exposure | |
| US5929093A (en) | Bifunctional acetylcholinesterase reactivators | |
| EP3464336B1 (en) | Compounds | |
| JP2022510691A (ja) | 線維症及び炎症の処置のための組成物 | |
| US11746089B2 (en) | Compounds and methods for treating alcohol disorder | |
| EP4520752A1 (en) | Carebastine salt and use thereof | |
| CA3075414A1 (en) | Acetaminophen-pregabalin combinations and methods of treating pain | |
| HK40036032A (en) | Dantrolene prodrugs and methods of their use | |
| HK40036032B (en) | Dantrolene prodrugs and methods of their use | |
| RU2815017C2 (ru) | Пролекарства дантролена и способы их применения | |
| EP3678659B1 (en) | Methods of using dantrolene to treat exposure to a neurotoxic agent | |
| US10172831B2 (en) | Catalytic scavengers of organophosphates to potentiate butyrylcholinesterase (hBChE) as a catalytic bioscavenger and methods for making and using them | |
| CN103184196B (zh) | 磷脂酰乙醇胺基超氧化物歧化酶组合物及其制备方法 | |
| EP3106458B1 (en) | Maleic acid salt of anti-prion compound, method for producing the same, and pharmaceutical composition of the same | |
| Wang et al. | PEGylated organophosphorus hydrolase combined with butyrylcholinesterase: dual-enzyme synergistic biocatalysis for acute organophosphate poisoning | |
| HK1164831B (en) | Arginase inhibitors and methods of use | |
| HK1164831A (en) | Arginase inhibitors and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 JUN 2025 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 JUN 2025 |